Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (BIIB – Research Report), Apyx Medical (APYX – Research Report) and Phathom Pharmaceuticals (PHAT – Research Report).
In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Biogen, with a price target of $325.00. The company’s shares closed last Thursday at $289.77, close to its 52-week high of $292.45.
According to TipRanks.com, Syed is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $301.04 average price target, which is a 4.3% upside from current levels. In a report issued on October 26, Goldman Sachs also upgraded the stock to Buy with a $370.00 price target.
Apyx Medical (APYX)
Apyx Medical received a Hold rating from JMP Securities analyst David Turkaly today. The company’s shares closed last Thursday at $1.91.
According to TipRanks.com, Turkaly is a 2-star analyst with an average return of
Currently, the analyst consensus on Apyx Medical is a Strong Buy with an average price target of $12.33.
Phathom Pharmaceuticals (PHAT)
Needham analyst Joseph Stringer maintained a Buy rating on Phathom Pharmaceuticals today and set a price target of $38.00. The company’s shares closed last Thursday at $10.43.
According to TipRanks.com, Stringer is a 2-star analyst with an average return of
Phathom Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $28.00, implying a 190.8% upside from current levels. In a report released yesterday, JonesTrading also reiterated a Buy rating on the stock with a $30.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIIB: